Sorrento Therapeutics Total Liabilities 2010-2023 | SRNE
Sorrento Therapeutics total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
Sorrento Therapeutics Annual Total Liabilities
(Millions of US $) |
| 2022 |
$495 |
| 2021 |
$617 |
| 2020 |
$395 |
| 2019 |
$525 |
| 2018 |
$417 |
| 2017 |
$225 |
| 2016 |
$315 |
| 2015 |
$203 |
| 2014 |
$33 |
| 2013 |
$26 |
| 2012 |
$1 |
| 2011 |
$0 |
| 2010 |
$1 |
| 2009 |
$0 |
Sorrento Therapeutics Quarterly Total Liabilities
(Millions of US $) |
| 2023-06-30 |
$655 |
| 2023-03-31 |
$587 |
| 2022-12-31 |
$495 |
| 2022-09-30 |
$485 |
| 2022-06-30 |
$496 |
| 2022-03-31 |
$629 |
| 2021-12-31 |
$617 |
| 2021-09-30 |
$621 |
| 2021-06-30 |
$593 |
| 2021-03-31 |
$383 |
| 2020-12-31 |
$395 |
| 2020-09-30 |
$457 |
| 2020-06-30 |
$453 |
| 2020-03-31 |
$485 |
| 2019-12-31 |
$525 |
| 2019-09-30 |
$554 |
| 2019-06-30 |
$532 |
| 2019-03-31 |
$491 |
| 2018-12-31 |
$417 |
| 2018-09-30 |
$364 |
| 2018-06-30 |
$193 |
| 2018-03-31 |
$196 |
| 2017-12-31 |
$225 |
| 2017-09-30 |
$346 |
| 2017-06-30 |
$289 |
| 2017-03-31 |
$283 |
| 2016-12-31 |
$315 |
| 2016-09-30 |
$207 |
| 2016-06-30 |
$216 |
| 2016-03-31 |
$185 |
| 2015-12-31 |
$203 |
| 2015-09-30 |
$179 |
| 2015-06-30 |
$42 |
| 2015-03-31 |
$31 |
| 2014-12-31 |
$33 |
| 2014-09-30 |
$33 |
| 2014-06-30 |
$32 |
| 2014-03-31 |
$31 |
| 2013-12-31 |
$26 |
| 2013-09-30 |
$7 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$1 |
| 2010-12-31 |
$1 |
| 2010-09-30 |
$0 |
| 2010-06-30 |
$0 |
| 2010-03-31 |
$0 |
| 2009-12-31 |
$0 |
| 2009-09-30 |
$0 |
| 2009-06-30 |
$0 |
| 2009-03-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.013B |
$0.063B |
|
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.
|
